Related Experiment Video
Updated: Aug 17, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
[Clostridioides difficile: updated recommendations].
Frédéric Barbut1, Catherine Eckert2, Valérie Lalande2
1Laboratoire Clostridioides difficile associé au CNR des bactéries anaérobies et du botulisme, hôpital Saint-Antoine, AP-HP, Paris, France - Unité de prévention du risque infectieux, hôpital Saint-Antoine, AP-HP, Paris, France. - Département de bactériologie, hôpital Saint-Antoine, AP-HP, Paris, France.
Updated Clostridioides difficile infection (CDI) guidelines address diagnosis and treatment. New recommendations incorporate advances in understanding CDI epidemiology, diagnostics, and therapies, including novel drugs and fecal microbiota transplantation.
Area of Science:
- Microbiology and Infectious Diseases
- Clinical Medicine
Context:
- Clostridioides difficile is an anaerobic enteropathogen causing a range of illnesses, from mild diarrhea to severe disease and death.
- Risk factors for C. difficile infection (CDI) include advanced age, hospitalization, and antibiotic use.
- The emergence of hypervirulent strains has spurred research into CDI.
Purpose:
- To update management recommendations for Clostridioides difficile infection (CDI) based on recent scientific advances.
- To provide guidance on the diagnosis and treatment of CDI.
- To emphasize prevention strategies including antimicrobial stewardship and contact precautions.
Summary:
- Recent advances in understanding CDI epidemiology, diagnosis (molecular tests), and therapy (fidaxomicin, bezlotoxumab, fecal microbiota transplantation) have necessitated updated guidelines.
- Treatment strategies for CDI are tailored to infection severity and recurrence risk.
- Prevention involves antimicrobial stewardship and contact precautions for infected patients.
Impact:
- Facilitates evidence-based clinical decision-making for managing CDI.
- Aims to improve patient outcomes by optimizing treatment and prevention strategies.
- Contributes to controlling the spread of C. difficile infections in healthcare settings.
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

